- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: Disability adjusted life years.
Displaying page 1 of 1.
EudraCT Number: 2019-003076-39 | Sponsor Protocol Number: ARGX-113-1802 | Start Date*: 2020-06-25 | |||||||||||
Sponsor Name:argenx BVBA | |||||||||||||
Full Title: A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) HU (Completed) ES (Completed) LV (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) BG (Completed) DK (Completed) AT (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005443-14 | Sponsor Protocol Number: NGAM-08 | Start Date*: 2017-04-28 | |||||||||||
Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H. | |||||||||||||
Full Title: Prospective, double-blind, randomized, multicenter phase III study evaluating efficacy and safety of three different dosages of NewGam in patients with chronic inflammatory demyelinating poly(radic... | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Poly(radiculo)-neuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000636-15 | Sponsor Protocol Number: 12/201/02 | Start Date*: 2015-05-27 |
Sponsor Name:Bangor University | ||
Full Title: A randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica. | ||
Medical condition: Sciatica is a symptom defined as unilateral, well-localised leg pain, with a sharp, shooting or burning quality, that approximates to the dermatomal distribution of the sciatic nerve down the poste... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-002751-25 | Sponsor Protocol Number: RG112-14 | Start Date*: 2014-10-08 | |||||||||||
Sponsor Name:The Walton Centre NHS Foundation Trust | |||||||||||||
Full Title: Multi-centre randomised control trial comparing the clinical and cost effectiveness of trans-foraminal epidural steroid injection to surgical microdiscectomy for the treatment of chronic radicular ... | |||||||||||||
Medical condition: Chronic radicular pain secondary to a prolapsed intervertebral disc herniation | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004505-16 | Sponsor Protocol Number: CONVINCE | Start Date*: 2016-08-08 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:University College Dublin | ||||||||||||||||||||||||||||||||||||||
Full Title: CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic stroke) – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke | ||||||||||||||||||||||||||||||||||||||
Medical condition: The prevention of recurrent stroke and coronary events (fatal and non- fatal) after ischaemic stroke and transient ischaemic attack (TIA) not caused by cardiac embolism or other causes unrelated to... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: IE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) DK (Completed) PT (Completed) BE (Completed) LT (Completed) NL (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002729-21 | Sponsor Protocol Number: VUMC-ARC-GLORIA | Start Date*: 2016-04-25 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Comparing the cost-effectiveness and safety of additional low-dose glucocorticoid in treatment strategies for elderly patients with... | |||||||||||||
Medical condition: Rheumatoid artritis | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) SK (Completed) FI (Prematurely Ended) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000618-32 | Sponsor Protocol Number: GNC-501 | Start Date*: 2022-09-29 | ||||||||||||||||
Sponsor Name:GENEURO SA | ||||||||||||||||||
Full Title: Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID-19 or Postacute Sequelae of COVID-19 (PASC) Sy... | ||||||||||||||||||
Medical condition: Postacute Sequelae of COVID-19 (PASC) Syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003219-22 | Sponsor Protocol Number: LMS/SF/UH/0018 | Start Date*: 2014-01-27 | |||||||||||
Sponsor Name:Hertfordshire Partnership University NHS Foundation Trust [...] | |||||||||||||
Full Title: A randomised controlled feasibility trial comparing clinical and cost effectiveness of cognitive behavioural therapy (CBT) and selective serotonin reuptake inhibitors (SSRI) and their combination i... | |||||||||||||
Medical condition: Obsessive Compulsive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000184-40 | Sponsor Protocol Number: 20130173 | Start Date*: 2014-09-11 | |||||||||||
Sponsor Name:Amgen, Inc. | |||||||||||||
Full Title: Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta | |||||||||||||
Medical condition: Osteogenesis Imperfecta | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) Outside EU/EEA BG (Completed) PL (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002567-24 | Sponsor Protocol Number: M120204-063 | Start Date*: 2005-04-04 |
Sponsor Name:Millennium Pharmaceuticals, Inc. | ||
Full Title: A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis | ||
Medical condition: The purpose of this study is to investigate the safety, PK parameters, PD responses, and clinical responses of multiple dose administration of MLN1202 in patients with relapsing remitting multiple ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) GB (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001426-57 | Sponsor Protocol Number: Penta21 | Start Date*: 2023-04-25 |
Sponsor Name:Fondazione Penta Onlus | ||
Full Title: A randomised non-inferiority trial with nested PK to assess DTG/3TC fixed dose formulations for the maintenance of virological suppression in children with HIV infection aged 2 to <15 years old | ||
Medical condition: HIV Infection | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002460-13 | Sponsor Protocol Number: VITDALIZE | Start Date*: 2017-01-03 |
Sponsor Name:Medical University of Graz | ||
Full Title: Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a multicenter, placebo-controlled double-blind phase III RCT | ||
Medical condition: Adult critically ill patients with severe vitamin D deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000406-35 | Sponsor Protocol Number: UX023-CL201 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Ultragenyx Pharmaceuticals Inc. | |||||||||||||
Full Title: A Randomized, open Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the anti-FGF23 antibody, KRN23, in Pediatric Patients with X-linked Hypophosphatemia (XLH) | |||||||||||||
Medical condition: X-linked hypophosphatemia (XLH) is a disorder of renal phosphate wasting, and the most common heritable form of rickets. In XLH patients, high circulating levels of fibroblast growth factor 23 (FG... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005309-35 | Sponsor Protocol Number: CL04041024 | Start Date*: 2017-06-16 | |||||||||||
Sponsor Name:R-Pharm | |||||||||||||
Full Title: A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis | |||||||||||||
Medical condition: Moderately to Severely Active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) LT (Completed) CZ (Completed) HU (Completed) PL (Completed) BG (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002148-56 | Sponsor Protocol Number: ACT-CS-005 | Start Date*: 2021-07-22 | |||||||||||
Sponsor Name:ACTICOR BIOTECH | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE BLIND, MULTICENTER, MULTINATIONAL, PLACEBO CONTROLLED, PARALLEL GROUP, SINGLE DOSE, ADAPTIVE EFFICACY AND SAFETY STUDY OF GLENZOCIMAB USED AS AN ADD-ON THERAPY ON TOP OF STANDA... | |||||||||||||
Medical condition: Acute ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) SK (Completed) ES (Ongoing) CZ (Completed) DK (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000133-40 | Sponsor Protocol Number: 2016-2369 | Start Date*: 2016-05-25 |
Sponsor Name:Gustave Roussy | ||
Full Title: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | ||
Medical condition: Relapsed or refractory tumors in children | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
